Saturation That Will Not Budge on a Non-Rebreather

This is a saturation gap: the oxygen tension is high but the measured saturation is low, which localizes the problem to hemoglobin, not to the lungs.

Pulse oximeters compare light absorption at two wavelengths (approximately 660 and 940 nm) and compute a ratio from assumed two-species behavior. Methemoglobin absorbs strongly and nearly equally at both wavelengths, so the ratio approaches 1 and the displayed value converges toward roughly 85%, almost regardless of true arterial saturation. That is why the number sits at 88% and does not move when FIO2 goes from room air to 15 L/min.

Discriminators:

• Hypoxemia: low PaO2, and the saturation rises promptly with supplemental oxygen. Here PaO2 is 205 mmHg.
• Carboxyhemoglobin: normal PaO2, saturation displayed falsely high or normal, and co-oximetry is required; the patient is usually a smoker or fire victim without the oxidant exposure.
• Methemoglobin: cyanosis unresponsive to oxygen, dark chocolate-colored blood, normal PaO2, and a saturation gap confirmed by co-oximetry (here 41%).

A normal plethysmograph and normal perfusion pressure argue against poor signal quality. The calculated saturation of 99% from the blood gas is derived from PaO2 and is not a measurement - it must be ignored in this setting.

Stop the benzocaine, support oxygenation and ventilation, secure the airway if mental status or ventilation deteriorates, and confirm with co-oximetry.

Methylene blue 1–2 mg/kg IV over 5 minutes (1% solution, 10 mg/mL). It is reduced to leukomethylene blue, which reduces methemoglobin back to hemoglobin. Repeat 0.5–1 mg/kg if methemoglobin remains above 30% or symptoms persist; response usually occurs within 30–60 minutes. Treat because the level is 41% with symptoms, not because of the number alone.

Cautions that change the plan:

• G6PD deficiency: methylene blue is ineffective and can precipitate hemolysis; ask before giving it. Alternatives are ascorbic acid 1–2 g IV, exchange transfusion, or hyperbaric oxygen for severe cases.
• Serotonergic drugs (SSRIs, MAOIs, tramadol, triptans): methylene blue is a potent MAO-A inhibitor and can precipitate serotonin toxicity, particularly at higher doses; use the lowest effective dose and monitor.
• Renal impairment: reduced clearance with repeated dosing.
• Pregnancy: avoid near term if possible.

Also recognize that methylene blue interferes with pulse oximetry and can transiently lower SpO2 readings; trend co-oximetry rather than the oximeter. If the patient were unstable or unable to protect the airway, intubate before definitive therapy and plan for admission rather than discharge.

Three 1-second bursts of 20% benzocaine deliver roughly 600 mg, well above the dose at which methemoglobinemia is described, and topical benzocaine is the single most common cause in endoscopy suites. The failure is not one person's error but a missing control:

• Dose standardization: pharmacy-prepared atomizers with a fixed volume per spray, or substitution of lidocaine, which is far less oxidizing. Weight-based maximum doses posted on the cart.
• Explicit screening: a pre-procedure question about prior reactions to topical anesthetics, G6PD deficiency, and dapsone or nitrite exposure.
• Monitoring long enough: methemoglobinemia appeared 20 minutes after exposure; the recovery area must be able to measure co-oximetry, not just SpO2, and staff must know that a saturation that does not respond to oxygen is a hemoglobin problem.
• A saturation-gap pathway: any patient with a saturation gap gets an ABG with co-oximetry, and the on-call anesthesia team is called rather than escalating oxygen alone.
• Documentation and reporting: file a safety report so the topical anesthetic policy is reviewed for the whole endoscopy service, and counsel the patient about the episode and future avoidance of benzocaine.